<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Intensive Care</journal-id><journal-id journal-id-type="iso-abbrev">Ann Intensive Care</journal-id><journal-title-group><journal-title>Annals of Intensive Care</journal-title></journal-title-group><issn pub-type="epub">2110-5820</issn><publisher><publisher-name>Springer Paris</publisher-name><publisher-loc>Paris</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27154719</article-id><article-id pub-id-type="pmc">4859323</article-id><article-id pub-id-type="publisher-id">147</article-id><article-id pub-id-type="doi">10.1186/s13613-016-0147-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Design and conduct of the activated protein C and corticosteroids for human septic shock (APROCCHSS) trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Annane</surname><given-names>Djillali</given-names></name><address><phone>33147107786</phone><email>djillali.annane@aphp.fr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Buisson</surname><given-names>Christian Brun</given-names></name><address><email>christian.brun-nuisson@aphp.fr</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cariou</surname><given-names>Alain</given-names></name><address><email>alain.cariou@aphp.fr</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Claude</given-names></name><address><email>ClaudeDenis.MARTIN@ap-hm.fr</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Misset</surname><given-names>Benoit</given-names></name><address><email>bmisset@hpsj.fr</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Renault</surname><given-names>Alain</given-names></name><address><email>alain.renault@chu-rennes.fr</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Lehmann</surname><given-names>Blandine</given-names></name><address><email>blandine.lehmann@aphp.fr</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Millul</surname><given-names>Val&#x000e9;rie</given-names></name><address><email>valerie.millul@gmail.org</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Maxime</surname><given-names>Virginie</given-names></name><address><email>virginie.maxime@aphp.fr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bellissant</surname><given-names>Eric</given-names></name><address><email>eric.bellissant@univ-rennes1.fr</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><collab>The APROCCHSS Investigators for the TRIGGERSEP Network</collab></contrib><aff id="Aff1"><label>1</label>General ICU, Service de R&#x000e9;animation, H&#x000f4;pital Raymond Poincar&#x000e9;, Laboratory of Infection and Inflammation, U1173, AP-HP, University of Versailles SQY and INSERM, 104 Boulevard Raymond Poincar&#x000e9;, 92380 Garches, France </aff><aff id="Aff2"><label>2</label>Service de R&#x000e9;animation M&#x000e9;dicale, H&#x000f4;pital Henri Mondor, AP-HP, Cr&#x000e9;teil, France </aff><aff id="Aff3"><label>3</label>Service de R&#x000e9;animation M&#x000e9;dicale, H&#x000f4;pital Cochin, AP-HP, Paris, France </aff><aff id="Aff4"><label>4</label>Service d&#x02019;Anesth&#x000e9;sie R&#x000e9;animation, H&#x000f4;pital Nord, AP-HM, Marseille, France </aff><aff id="Aff5"><label>5</label>Service de M&#x000e9;decine Intensive et R&#x000e9;animation, H&#x000f4;pital Saint-Joseph, AP-HP, Universit&#x000e9; Paris Descartes, Paris Sorbonne Cit&#x000e9;, Paris, France </aff><aff id="Aff6"><label>6</label>Service de Pharmacologie, Centre d&#x02019;Investigation Clinique INSERM 1414, CHU de Rennes, Universit&#x000e9; de Rennes 1, Rennes, France </aff><aff id="Aff7"><label>7</label>D&#x000e9;partement des Essais Cliniques, AGEPS, Paris, France </aff><aff id="Aff8"><label>8</label>D&#x000e9;l&#x000e9;gation &#x000e0; la Recherche Clinique, H&#x000f4;pital Saint-Louis, AP-HP, Paris, France </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>6</volume><elocation-id>43</elocation-id><history><date date-type="received"><day>3</day><month>3</month><year>2016</year></date><date date-type="accepted"><day>22</day><month>4</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; Annane et al. 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p> We aimed at assessing the benefit-to-risk ratio of activated protein C (drotrecogin-alfa activated, DAA) and corticosteroids, given alone or in combination, in patients with septic shock.</p></sec><sec><title>Methods</title><p> We implemented an investigator-led, publicly funded, multicenter, randomized according to a 2&#x000a0;&#x000d7;&#x000a0;2 factorial design, placebo-controlled, double-blind trial in four parallel groups in which adults with persistent septic shock and no contraindication to DAA were assigned to either DAA alone (24&#x000a0;mg/kg/h for 96&#x000a0;h), or hydrocortisone (50&#x000a0;mg intravenous bolus q6 for 7&#x000a0;days) and fludrocortisone (50&#x000a0;&#x000b5;g once daily through the nasogastric tube for 7&#x000a0;days) alone, or their respective combinations, or their respective placebos. Primary endpoint was 90-day mortality rate. Follow-up duration was 6&#x000a0;months. Statistical analysis was planned to be performed in intent-to-treat once after all participants completed 180-day follow-up and according to the 2&#x000a0;&#x000d7;&#x000a0;2 factorial design.</p></sec><sec><title>Results</title><p>The first patient was recruited in September 2008. The trial was suspended on October 25, 2011, owing to the withdrawal from the market of DAA. At this time, 411 patients had been enrolled. On May 17, 2012, the continuation of the trial on two parallel groups was approved by all legal authorities with the aim of investigating the benefit-to-risk ratio of corticosteroids. On June 30, 2014, the trial was suspended again by the study sponsor upon request of the independent data and safety monitoring board. Recruitment restarted on October 7, 2014, after any safety concern was ruled out. Finally, the trial was completed on June 23, 2015, with the recruitment of 1241 patients.</p></sec><sec><title>Conclusions</title><p>This report details the design, statistical plan and conduct of a randomized controlled trial of hydrocortisone and fludrocortisone in septic shock.</p><p><italic>Trial registration</italic> The trial was registered at ClinicalTrials.gov under NCT00625209</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Septic shock</kwd><kwd>Clinical trial</kwd><kwd>Design</kwd><kwd>Ethics</kwd><kwd>Corticosteroids</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004726</institution-id><institution>Ministry of Health</institution></institution-wrap></funding-source><award-id>Ministry of Health contract number P090902 and contract P 12-002-0030</award-id><principal-award-recipient><name><surname>Annane</surname><given-names>Djillali</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Septic shock is now defined by a vasopressor requirement to maintain a mean arterial pressure &#x02265;65&#x000a0;mmHg and serum lactate &#x0003e;2&#x000a0;mmol/l in the absence of hypovolemia [<xref ref-type="bibr" rid="CR1">1</xref>] (it was defined by the need for vasopressors to restore cardiovascular homeostasis [<xref ref-type="bibr" rid="CR2">2</xref>] at the time the protocol was planned). Its mortality and sequalae remain unacceptably high with roughly one out of two patients dying within 1&#x000a0;year and half of survivors suffering from cognitive decline [<xref ref-type="bibr" rid="CR3">3</xref>]. International guidelines recommend immediate source control and antibiotics, fluid resuscitation and norepinephrine [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p> Drotrecogin-alfa activated (DAA) was the only marketed therapy for sepsis after promising early findings [<xref ref-type="bibr" rid="CR5">5</xref>]. Subsequent investigations failed to reproduce survival benefit from this drug in sepsis [<xref ref-type="bibr" rid="CR6">6</xref>] or in septic shock [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p><p>Corticosteroids have been used for more than 60&#x000a0;years, mainly in inflammatory conditions, autoimmune diseases or cancer. They have also been used in infectious diseases and sepsis. Corticosteroids have pleiotropic effects including immune modulation, metabolic and cardiovascular effects. So far, sepsis trials have failed to rule in or out survival benefit from corticosteroids. Most physicians and researchers would agree against using short course (&#x0003c;3&#x000a0;days) of high dose (&#x0003e;400&#x000a0;mg per day of hydrocortisone or equivalent) in sepsis [<xref ref-type="bibr" rid="CR4">4</xref>]. Treatment with &#x02264;400&#x000a0;mg per day of hydrocortisone (or equivalent) for &#x02265;3&#x000a0;days has variably been associated with survival benefit [<xref ref-type="bibr" rid="CR9">9</xref>]. The two largest trials of corticosteroids for septic shock with 300 [<xref ref-type="bibr" rid="CR10">10</xref>] and 500 [<xref ref-type="bibr" rid="CR11">11</xref>] patients, respectively, reported treatment benefits in terms of hemodynamics and organ functions. One trial showed survival benefit in septic shock and blunted cortisol response to corticotrophin [<xref ref-type="bibr" rid="CR10">10</xref>]. There were remarkable differences in trials&#x02019; design (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Current guidelines suggest restricting hydrocortisone to patients who are poorly responsive to vasopressors, not using fludrocortisone and not based on Synacthen test [<xref ref-type="bibr" rid="CR4">4</xref>].<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Comparison of (a) targeted population, (b) experimental treatments of four trials on corticosteroids for septic shock</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Ger-Inf-05</th><th align="left">CORTICUS</th><th align="left">APROCCHSS</th><th align="left">ADRENALS</th></tr></thead><tbody><tr><td align="left" colspan="5">(a)</td></tr><tr><td align="left">Expected sample size</td><td align="left">300</td><td align="left">800</td><td align="left">1240</td><td align="left">3800</td></tr><tr><td align="left">Actual sample size</td><td align="left">300</td><td align="left">500</td><td align="left">1241</td><td align="left">?</td></tr><tr><td align="left">Time window for inclusion since onset of shock</td><td align="left">3&#x000a0;h then protocol amended for 8&#x000a0;h</td><td align="left">72&#x000a0;h</td><td align="left">24&#x000a0;h</td><td align="left">24&#x000a0;h</td></tr><tr><td align="left">Age</td><td align="left">&#x02265;18&#x000a0;years</td><td align="left">&#x02265;18&#x000a0;years</td><td align="left">&#x02265;18&#x000a0;years</td><td align="left">&#x02265;18&#x000a0;years</td></tr><tr><td align="left">Shock criteria</td><td align="left">SBP&#x000a0;&#x0003c;&#x000a0;90&#x000a0;mm Hg for at least 1&#x000a0;h despite adequate fluid replacement and &#x0003e;5&#x000a0;&#x003bc;g/kg/h of dopamine or epinephrine or norepinephrine;<break/>Arterial lactate &#x0003e;2&#x000a0;mmol/l</td><td align="left">SBP&#x000a0;&#x0003c;&#x000a0;90&#x000a0;mmHg or decrease &#x0003e;50&#x000a0;mmHg in SBP in previous hypertensive patients despite adequate fluid replacement or need for vasopressors to maintain SBP&#x000a0;&#x02265;&#x000a0;90&#x000a0;mmHg<break/>Administration of vasopressor for &#x02265;1&#x000a0;h</td><td align="left">Norepinephrine or epinephrine at a rate &#x02265;0.25&#x000a0;&#x000b5;g/kg/min or &#x02265;1&#x000a0;mg/h) or any other vasopressor to maintain SBP&#x000a0;&#x02265;&#x000a0;90&#x000a0;mmHg or MBP&#x000a0;&#x02265;&#x000a0;65&#x000a0;mmHg<break/>Administration of vasopressors for &#x02265;6&#x000a0;h</td><td align="left">Vasopressors or inotropes to maintain a SBP&#x000a0;&#x0003e;&#x000a0;90&#x000a0;mmHg, or MBP&#x000a0;&#x0003e;&#x000a0;60&#x000a0;mmHg, or a MBP target set by the treating clinician for maintaining perfusion<break/>Administration of vasopressors or inotropes for =4&#x000a0;h</td></tr><tr><td align="left">Mechanical ventilation as a mandatory entry criteria</td><td align="left">Yes</td><td align="left">No</td><td align="left">No</td><td align="left">Yes</td></tr><tr><td align="left">Organ failure</td><td align="left">Urinary output of &#x0003c;0.5&#x000a0;ml/kg for &#x02265;1&#x000a0;h<break/>Or PaO<sub>2</sub>/FIO<sub>2</sub>&#x000a0;&#x0003c;&#x000a0;280&#x000a0;mmHg</td><td align="left">Urine output &#x0003c;0.5&#x000a0;ml/kg/h for &#x02265;1&#x000a0;h<break/>Or pH&#x000a0;&#x0003c;&#x000a0;7.3, or arterial base deficit &#x02265;5.0&#x000a0;mmol/l, or arterial lactate &#x0003e;2&#x000a0;mmol/l<break/>Or PaO<sub>2</sub>/FIO<sub>2</sub>&#x000a0;&#x0003c;&#x000a0;280 in the absence of pneumonia, and &#x0003c;200 in the presence of pneumonia<break/>Or platelet count &#x02264;100,000 cells/mm<sup>3</sup>
<break/>Or Glasgow Coma Scale &#x0003c;14 or acute change from baseline)</td><td align="left">Sequential Organ Failure Assessment (SOFA) score &#x02265;3 for &#x02265;2 organs for &#x02265;6 consecutive hours</td><td align="left">Not mentioned</td></tr><tr><td align="left">Non-responders to the Synacthen test as the primary subgroup of interest</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">No</td></tr><tr><td align="left" colspan="5">(b)</td></tr><tr><td align="left">Type of corticosteroids</td><td align="left">Hydrocortisone hemisuccinate and 9-&#x003b1;-fludrocortisone</td><td align="left">Hydrocortisone hemisuccinate</td><td align="left">Hydrocortisone hemisuccinate and 9-&#x003b1;-fludrocortisone</td><td align="left">Hydrocortisone</td></tr><tr><td align="left">Dose per day</td><td align="left">Hydrocortisone 200&#x000a0;mg<break/>Fludrocortisone 50&#x000a0;&#x000b5;g</td><td align="left">200&#x000a0;mg</td><td align="left">Hydrocortisone 200&#x000a0;mg<break/>Fludrocortisone 50&#x000a0;&#x000b5;g</td><td align="left">200&#x000a0;mg</td></tr><tr><td align="left">Route of administration</td><td align="left">Hydrocortisone: four intravenous bolus of 50&#x000a0;mg<break/>Fludrocortisone: 50&#x000a0;&#x000b5;g via the nasogastric tube</td><td align="left">Four intravenous bolus of 50&#x000a0;mg</td><td align="left">Hydrocortisone: four intravenous bolus of 50&#x000a0;mg<break/>Fludrocortisone: 50&#x000a0;&#x000b5;g via the nasogastric tube</td><td align="left">Intravenous continuous infusion rate without loading dose</td></tr><tr><td align="left">Duration</td><td align="left">Seven days at full dose</td><td align="left">Five days at full dose then tapered to 50&#x000a0;mg intravenously every 12&#x000a0;h for days 6 to 8, 50&#x000a0;mg every 24&#x000a0;h for days 9 to 11, and then stopped</td><td align="left">Seven days at full dose</td><td align="left">Seven days at full dose, while in the ICU</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec2"><title>Description of the study design</title><sec id="Sec3"><title>Clinical question and trial objectives</title><p>On the one hand, there was a strong rationale for using DAA or corticosteroids in sepsis [<xref ref-type="bibr" rid="CR12">12</xref>]. DAA may act via direct immunomodulation and by counteracting sepsis-induced hypercoagulopathy [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. It was associated with survival benefit in a phase III trial in severe sepsis [<xref ref-type="bibr" rid="CR5">5</xref>]. The hypothalamic&#x02013;pituitary&#x02013;adrenal (HPA) axis was identified as the main endogenous counter-regulator of inflammation [<xref ref-type="bibr" rid="CR14">14</xref>]. Then, disrupted HPA axis and exaggerated inflammation may favor multiple organ failure and death in sepsis [<xref ref-type="bibr" rid="CR15">15</xref>]. Corticosteroids were associated in Ger-Inf-05 [<xref ref-type="bibr" rid="CR10">10</xref>], a phase III trial of hydrocortisone plus fludrocortisone, with survival benefit in septic shock and post-corticotrophin increase in cortisol levels &#x02264;9&#x000a0;&#x000b5;g/dl, so-called non-responders [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p>On the other hand, there was equipoise among physicians about routine use of DAA and corticosteroids [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Although DAA was approved for sepsis, failure to confirm its benefit in mild sepsis [<xref ref-type="bibr" rid="CR6">6</xref>] yielded controversy about its benefits and risks with limited use in routine practice. Likewise, CORTICUS cast doubt about the benefit of hydrocortisone [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p>Therefore, the activated protein C and corticosteroids for human septic shock (APROCCHSS) trial aimed at evaluating in septic shock the benefit-to-risk ratio of DAA and corticosteroids, given alone or in combination, and any interaction between response to corticosteroids and non-responder status.</p></sec><sec id="Sec4"><title>Study design</title><p>We designed an investigator-led, publicly funded, multicenter, randomized, 2&#x000a0;&#x000d7;&#x000a0;2 factorial, placebo-controlled, double-blind trial in four parallel groups.</p></sec><sec id="Sec5"><title>Selection of study population</title><p>Evidence suggested greater benefit from DAA or corticosteroids in septic shock than in sepsis, in adults than in children, and when administered within 24&#x000a0;h [<xref ref-type="bibr" rid="CR12">12</xref>]. In routine practice, physicians may consider adjunct therapy after optimal management of sepsis source and of organs function [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p>Therefore, were eligible in the trial, adults admitted to the intensive care unit (ICU) for &#x0003c;7&#x000a0;days and with indisputable or probable septic shock [<xref ref-type="bibr" rid="CR2">2</xref>] for &#x0003c;24&#x000a0;h. Septic shock was defined by (1) clinically or microbiologically documented infection, (2) Sequential Organ Failure Assessment (SOFA) [<xref ref-type="bibr" rid="CR19">19</xref>] score &#x02265;3 for &#x02265;2 organs for &#x02265;6 consecutive hours, (3) treatment for &#x02265;6&#x000a0;h with catecholamines (&#x02265;0.25&#x000a0;&#x000b5;g/kg/min or &#x02265;1&#x000a0;mg/h of norepinephrine, epinephrine or any other vasopressor) to maintain systolic (SBP) &#x02265;90&#x000a0;mmHg or mean blood pressure (MBP) &#x02265;65&#x000a0;mmHg. Patient&#x02019;s informed consent or next of kin assent was obtained before inclusion whenever possible. Otherwise, deferred consent from patients was recorded [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p>Owing to the risk of bleeding with DAA [<xref ref-type="bibr" rid="CR21">21</xref>], non-inclusion criteria were (1) surgical procedure &#x02264;7&#x000a0;days; (2) gastrointestinal bleeding &#x02264;6&#x000a0;weeks; (3) chronic liver disease; (4) trauma &#x02264;3&#x000a0;months; (5) any intracranial mass, stroke or head injury &#x02264;3&#x000a0;months; (6) thrombocytopenia &#x0003c;30,000/mm<sup>3</sup>; (7) formal indication for anticoagulation except venous thromboembolism prophylaxis which should be continued whenever indicated; (8) any other condition with increased risk of bleeding, as per patient&#x02019;s physician. Owing to uncertainty of effects of DAA or corticosteroids in pregnant women and in newborns, patients were not included in case of pregnancy or lactation. Additional non-inclusion criteria were (1) patients with palliative goals, (2) underlying fatal (&#x02264;1&#x000a0;month) condition, (3) patients currently taking corticosteroids (30&#x000a0;mg prednisone equivalent &#x02265;1&#x000a0;month), (4) known hypersensitivity to DAA, (5) no affiliation to social security.</p><p>A priori defined subgroups of interest to explore survival benefits from corticosteroids were: (1) non-responders, i.e., patients who increase their cortisol levels by 9&#x000a0;&#x000b5;g/dl or less at 30 and 60&#x000a0;min following 250&#x000a0;&#x000b5;g intravenous bolus of corticotrophin; (2) community-acquired pneumonia; (3) acute respiratory distress syndrome (ARDS). Indeed, it was expected that non-responders, patients with community-acquired pneumonia or ARDS may be more likely to draw survival benefit from corticosteroids [<xref ref-type="bibr" rid="CR9">9</xref>].</p></sec><sec id="Sec6"><title>Study interventions</title><p>DAA was infused intravenously at 24&#x000a0;&#x003bc;g/kg/h from foil-wrapped bags for 96&#x000a0;h. Infusion was interrupted 2&#x000a0;h before any percutaneous procedure or major surgery and resumed 1 or 12&#x000a0;h later, respectively, in the absence of bleeding complication. Identical blinded volume of 0.9&#x000a0;% saline was used as placebo for DAA.</p><p>Type, dose and duration (7&#x000a0;days) of corticosteroids were determined according to Ger-Inf-05 [<xref ref-type="bibr" rid="CR10">10</xref>] and not to CORTICUS [<xref ref-type="bibr" rid="CR11">11</xref>]. Hydrocortisone was administered as 50&#x000a0;mg intravenous bolus every 6&#x000a0;h, and 50&#x000a0;&#x000b5;g tablet of fludrocortisone was given via the nasogastric tube once daily in the morning. Placebos of French commercial forms of hydrocortisone and fludrocortisone were manufactured for the requirements of the trial. Active and placebo drugs had similar aspects (checked and certified by qualified persons for each batch), i.e., vials of white, freeze-dried powder for parenteral use of hydrocortisone hemisuccinate 100&#x000a0;mg or placebo, and tablets for oral fludrocortisone 50&#x000a0;&#x000b5;g or placebo in blisters of ten.</p><p>Co-interventions were harmonized across centers according to 2008 Surviving Sepsis Campaign guidelines [<xref ref-type="bibr" rid="CR22">22</xref>]. Blood glucose levels were monitored at least every 4&#x000a0;h and maintained at &#x02264;150&#x000a0;mg/dl by intravenous infusion of insulin. Intravenous broad-spectrum antibiotics were given after drawing specimen from all potential sites of infection and adjusted to actual pathogens whenever needed. Investigators followed guidelines for the prevention of superinfection [<xref ref-type="bibr" rid="CR23">23</xref>]. Open-labeled corticosteroids and non-steroidal anti-inflammatory drugs, open-labeled DAA, anti-thrombin III and any anticoagulant (except venous thromboembolism prophylaxis) were discouraged. The use of antiplatelet agents was left at physicians&#x02019; discretion. Neuromuscular blockade agents were discouraged, except in the first 24&#x000a0;h of refractory hypoxia. The investigators were provided with published guidelines for the management of septic shock. We systematically recorded, on a daily basis during the first week post-randomization, in the case report form, blood glucose levels and dose and duration of insulin, source and pathogens identification and dose and duration of any antibiotic administered to the patients, type and dose of fluid therapy and of vasopressor therapy, score of sedation and delirium and use of any sedation or neuromuscular blocking drug, dose and duration of any anticoagulant, and type, dose and reason for use of any open-labeled corticosteroids. These data will allow careful examination of the adherence of investigators to guidelines for co-interventions. In addition, at each investigators meeting, these guidelines were systematically discussed to reinforce compliance.</p></sec><sec id="Sec7"><title>Randomization and blinding</title><p>Randomization was centralized, through a secured Web site, and stratified according to center, using permutation blocks where size was unknown by investigators. Patients were randomly allocated to receive DAA and hydrocortisone plus fludrocortisone, placebo of DAA and hydrocortisone plus fludrocortisone, or DAA and placebos of hydrocortisone and fludrocortisone, or all placebos. The day of randomization was considered as study day 0. The system printed prefilled prescriptions and, during the first part of the trial, individual infusion tables of DAA/placebo for care unit and pharmacy.</p><p>Treatment boxes were coded and masked centrally. Corticosteroids or placebos were sealed in sequentially numbered, identical boxes containing 30 vials of lyophilized hydrocortisone and 30 ampoules of injectable water, and a blister package with 10 tablets of fludrocortisone or its placebo. Each box has a detachable sticker for traceability of dispensing by hospital pharmacy and for administration by nurses.</p><p>Numbered boxes of DAA/placebo were also prepared on site. One patient received one corticosteroid/placebo box and one DAA/placebo box with the same randomization number. All study drugs were shipped to participating sites by AGEPS, AP-HP, Paris, France. The sequence was concealed from patients, staff members, investigators, members of independent data safety monitoring board (DSMB), sponsor and local pharmacists for corticosteroids.</p></sec><sec id="Sec8"><title>Definitions</title><p><italic>Organ system failure</italic> was defined for each of the 6 major organ systems as a SOFA score of 3 or 4 points (on a scale of 0&#x02013;4 for each organ system, for an aggregate score of 0&#x02013;24, with higher scores indicating more severe organ dysfunction) [<xref ref-type="bibr" rid="CR19">19</xref>]. <italic>Reversal of shock</italic> was defined as MBP&#x000a0;&#x02265;&#x000a0;60&#x000a0;mmHg for &#x02265;24&#x000a0;h after cessation of vasopressor. <italic>Superinfection</italic> was defined using standard criteria [<xref ref-type="bibr" rid="CR23">23</xref>], as a new infection occurring &#x02265;48&#x000a0;h after randomization. <italic>New sepsis</italic> was defined as a new episode with microbiologic confirmation. <italic>New septic shock</italic> was defined as a new episode of septic shock after reversal of the initial episode.</p></sec><sec id="Sec9"><title>Investigated parameters and follow-up</title><sec id="Sec10"><title>Baseline data</title><p>We systematically recorded (1) demographic and anthropometric data; (2) time of hospital and ICU admissions; (3) location prior to ICU admission (community, hospital, long-term care facility); (4) co-morbidities using Acute Physiology and Chronic Health Evaluation (APACHE) disability scale [<xref ref-type="bibr" rid="CR24">24</xref>] and McCabe class [<xref ref-type="bibr" rid="CR25">25</xref>]; (5) severity of illness using vital signs, Simplified Acute Physiology Score (SAPS) II [<xref ref-type="bibr" rid="CR26">26</xref>] and SAPS III [<xref ref-type="bibr" rid="CR27">27</xref>] and SOFA score [<xref ref-type="bibr" rid="CR19">19</xref>]; (6) core temperature; (7) type and dose of any antibiotics in the week before randomization; (8) type and dose of vasopressors and inotropic drugs; (9) time from shock onset; (10) hematologic, chemical data, blood gas analyses and arterial lactate levels; (11) Gram examination and cultures of samples from any suspected site of infection; (12) plasma cortisol levels before, 30 and 60&#x000a0;min after 250&#x000a0;&#x000b5;g intravenous bolus of corticotrophin.</p></sec><sec id="Sec11"><title>Follow-up</title><p>Patients were followed up for 180&#x000a0;days. We recorded daily from randomization to study day 7, at day 10, day 14, day 21 and day 28 or at ICU discharge (depending on which occurred first): (1) vital signs; (2) muscular disability rating score (MDRS) ranging from 1 to 5 with 1 meaning no deficit, 2 minimal deficit or atrophy, 3 mild-to-moderate distal deficit, 4 mild-to-moderate proximal deficit and 5 severe proximal deficit or atrophy [<xref ref-type="bibr" rid="CR28">28</xref>]; (3) CAM-ICU scale [<xref ref-type="bibr" rid="CR29">29</xref>]; (4) any bleeding; (5) results from standard laboratory tests; (6) cultures of specimens from any new suspected site of infection; (7) cumulated doses of intravenous insulin (UI/L/24&#x000a0;h), minimal and maximal infusion rates (&#x000b5;g/h; given for at least 1&#x000a0;h) of catecholamine, blood product transfusion, mode of ventilation (spontaneous breathing, noninvasive or invasive mechanical ventilation), need for and mode of renal replacement therapy and treatment with statins; (8) SOFA scores. If the patient was sedated, MDRS score and CAM-ICU were assessed &#x02265;6&#x000a0;h after interruption of sedation. In case of abnormal neurological status, brain imaging (CT scan or magnetic resonance imaging) was performed.</p><p>Mid-term sequalae were assessed at day 90 and day 180 post-randomization, by means of the Short-Form General Health Survey [<xref ref-type="bibr" rid="CR30">30</xref>], the Impact of Events scale [<xref ref-type="bibr" rid="CR31">31</xref>] and Hospital Anxiety and Depression scale [<xref ref-type="bibr" rid="CR32">32</xref>].</p></sec></sec><sec id="Sec12"><title>Biobanking</title><p>Fifteen milliliters of blood was sampled at baseline, day 1, day 4 and day 7. Then, aliquots of serum and plasma were stored at &#x02212;80&#x000a0;&#x000b0;C, and DNA was stored at +4&#x000a0;&#x000b0;C at each participating hospital. On a regularly basis, samples were shipped to a core laboratory.</p></sec><sec id="Sec13"><title>Study endpoints</title><p>Ninety-day mortality was the primary endpoint. Although most of sepsis-related deaths occur within 28&#x000a0;days, increasing evidence suggests that sepsis continues to kill patients beyond day 28. In previous sepsis trials, significant number of 28-day survivors died during the same hospital stay [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p> Secondary endpoints included (1) death rates at ICU and hospital discharge, at day 28 and day 180; (2) proportion of patients with decision to withhold/withdraw care; (3) time to wean off vasopressors, i.e., shock reversal; (4) number of days alive (up to 28 and 90&#x000a0;days) and free of vasopressors; (5) time to SOFA score &#x0003c;6; (6) number of days alive (up to 28 and 90&#x000a0;days) and with SOFA score &#x0003c;6; (7) time to wean off mechanical ventilation; (8) number of days alive (up to 28 and 90&#x000a0;days) and free of mechanical ventilation; (9) length of ICU and hospital stay in all patients and in survivors.</p><p>Safety outcomes included occurrence up to 90&#x000a0;days of superinfection, new sepsis, new septic shock, gastrointestinal bleeding and neurological sequalae (cognitive impairment and muscles weakness) at ICU and hospital discharge, at day 90 and at day 180.</p></sec><sec id="Sec14"><title>Sample size calculation and statistical analysis plan</title><p>We anticipated a 90-day mortality rate among patients with septic shock of 45&#x000a0;% [<xref ref-type="bibr" rid="CR10">10</xref>]. Using 2&#x000a0;&#x000d7;&#x000a0;2 factorial design with a bilateral formulation, 320 patients per group (i.e., total of 1280 patients) were needed to detect an absolute reduction of 10&#x000a0;% of 90-day mortality (<italic>&#x003b1;</italic>&#x000a0;=&#x000a0;0.05 and power at 95&#x000a0;%) with either DAA or corticosteroids.</p><p>After DAA withdrawal from the market, we analyzed the effects of DAA in patients included before trial suspension without analyzing the effects of corticosteroids [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p>As initially planned in the protocol, statistical analyses will be performed in intent-to-treat after all participants have completed 180-day follow-up and according to the 2&#x000a0;&#x000d7;&#x000a0;2 factorial design. This analysis will allow assessing the interaction between DAA and corticosteroids and corticosteroids effect (on the basis of a comparison of 2 groups of approximately 620 patients) with the initially planned power. The effect of DAA will be reanalyzed on the basis of a comparison including 208 patients with DAA and 1033 patients without DAA with a statistical power of 76&#x000a0;%.</p><p>For continuous variables, means and SD or median (IQR), in case of non-normality of distribution, will be reported. For categorical variables, number of patients in each category and corresponding percentages will be given. Missing data will not be replaced.</p><p>The effects of treatments on frequency of fatal events (mortality rates at day 28, at day 90, at discharge from ICU or from hospital and at day 180) will be compared using a logistic regression. The same analysis will be used for the proportion of patients with decision to withhold/withdraw care and safety outcomes. An analysis of variance will be used to compare continuous variables as length of stay. Cumulative event curves (censored endpoints) will be estimated with Kaplan&#x02013;Meier procedure, and Cox model will be used to compare treatments effects (time to death, time to wean off vasopressors and mechanical ventilation, time to a SOFA score &#x0003c;6). Analysis of variance will be used to compare number of days alive and free of vasopressors, mechanical ventilation, and with a SOFA score &#x0003c;6.</p><p>The same analyses will be conducted for subgroups unless the numbers of patients are insufficient. In this case, statistical methods will be adapted according to sample sizes.</p><p>The statistical analysis plan will be revised after blind review of data and before access to randomization list. All analyses will be conducted with SAS statistical software (version 9.4; Cary, NC, USA).</p></sec><sec id="Sec15"><title>Study Organization and Funding</title><p>The protocol was approved by all investigators on June 2007. It was independently approved for scientific and financial aspects by the national jury of the Clinical Research Hospital Program on October 2007, and the Ministry of Health confirmed funding under contract number P 070128. The protocol and qualification of all investigators were approved by the Ethics Committee (<italic>Comit&#x000e9; de Protection des Personnes</italic>, <italic>CPP</italic>) of Saint-Germain-en-Laye, France, on November 22, 2007. The CPP allowed for waiver of consent and deferred consent.</p><p>DSMB was set up prior to recruitment of the first patient, included experts in critical care medicine, infectious diseases, pharmacology and statistics, had full access to raw data and met on a regular basis.</p><p>Data monitoring was performed by the sponsor (<italic>AP</italic>-<italic>HP; D&#x000e9;l&#x000e9;gation &#x000e0; la Recherche Clinique d&#x02019;Ile de France, DRRC</italic>). AP-HP had full access to patients&#x02019; charts and checked all data recorded onto the electronic case report form (CRF) against original chart. The trial used a Web-based electronic CRF (Telemedecine Technology, France).</p><p>Data management and statistical analysis were performed independently of the sponsor and of investigators by specialized Biometry unit (<italic>Unit&#x000e9; de Biom&#x000e9;trie, INSERM 1414 Clinical Investigation Centre, Rennes University Hospital, Rennes 1 University, Rennes France</italic>).</p><p>Institutional pharmacists (AGEPS) were responsible for obtaining corticosteroids and their placebos, shipping study drugs to participating sites and getting back unused drugs. They were responsible for accurateness of blinding and pharmaceutical organization of the trial.</p><p>Vials of lyophilizate for parenteral use of hydrocortisone hemisuccinate 100&#x000a0;mg or placebo and diluent ampoules were obtained from Serb pharmaceutical company. Active and placebo tablets for oral route of fludrocortisone 50&#x000a0;&#x000b5;g were supplied from French commercial market under responsibility of AGEPS. Due to the study length, fludrocortisone shelf-life and commercial changes, different companies were involved: EP-HP AP-HP, Genopharm and HAC pharma company. No change in formulation, specifications or quality controls occurred. This was approved by National Agency for Drug Safety (ANSM, Saint-Denis, France). Anticipation of manufacturing campaigns avoided any supply disruption.</p><p>Several documents were provided to caregivers and pharmacists to ensure safety, compliance and good use of study drugs: prefilled prescriptions (with patient ID, weight, treatment number, DAA/placebo infusions description when required), DAA/placebo personalized administration table (number of perfusions, dose/perfusion, durations, etc.), DAA/placebo preparation sheet for hospital pharmacists, nurse tracking administration file, pharmacy dispensing and return book. All documents were revised after DAA withdrawal from the market.</p><p>A total of 65 ICU were authorized to recruit patients, 19 at university hospitals and 46 at community hospitals. Among them 34 participated actively in recruiting patients in this trial.</p></sec><sec id="Sec16"><title>Trial registration</title><p>The trial was registered on February 19, 2008, before inclusion of the first patient, at ClinicalTrials.gov under the number NCT00625209.</p></sec></sec><sec id="Sec17"><title>Study conduct</title><sec id="Sec18"><title>Study suspension and completion</title><p>The first patient was recruited on September 2, 2008, and the last patient on June 23, 2015. The study was suspended twice. Study sponsor, Steering committee, investigators, pharmacists and study statisticians always remained blinded to study treatments.</p><p>On October 25, 2011, while the trial was still recruiting, Lilly announced DAA withdrawal from the market [<xref ref-type="bibr" rid="CR34">34</xref>]. Since DAA was no longer available and Lilly refused to provide the drug for our study, AP-HP immediately suspended the study. The Steering committee, while remaining blinded to study treatments, proposed to analyze effects of DAA in the 411 patients included before trial suspension without analyzing effects of corticosteroids as there was no interaction between the two treatments. There was no benefit from DAA [<xref ref-type="bibr" rid="CR8">8</xref>]. The Steering committee recommended trial&#x02019;s continuation to assess effects of corticosteroids. These recommendations were approved by ethics committee on February 10, 2012, and by ANSM on April 18, 2012. Inclusions into the study restarted on May 18, 2012. On June 24, 2013, additional funding was granted from Ministry of Health (contract P 12-002-0030; AOM 07008).</p><p>On July 22, 2014, AP-HP decided to suspend the trial after DSMB requested careful examination of serious adverse events and checking study drugs quality. Subsequently, detailed description of all serious adverse events was provided for all patients. Meanwhile, independent investigations confirmed study drugs quality. DSMB advised on October 1, 2014, AP-HP to restart the trial. The trial continuation was approved on October 7, 2014 by ANSM and on November 13, 2014 by CPP. The trial was completed by December 23, 2015, after the last patient reached 180 day post-randomization. Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> shows the actual recruitment curve.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Cumulative number of enrolled patients in the trial</p></caption><graphic xlink:href="13613_2016_147_Fig1_HTML" id="MO1"/></fig></p><p>In April 2014, ANSM announced a shortage of Synacthen 0.25 in Europe. The trial was not suspended. Investigators and sites&#x02019; pharmacists asked to continue sampling for random cortisol measurement whenever Synacthen was not available at their hospital.</p></sec><sec id="Sec19"><title>Study protocol amendments</title><p>There were 29 amendments to study protocol (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). They were approved by investigators, study statistician, AP-HP, CPP and ANSM.<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>List of amendments to the protocol</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Amendments number</th><th align="left">Changes in protocol</th><th align="left">CPP approval date</th><th align="left">ANSM approval date</th><th align="left">Official version of trial protocol</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">Changes in following exclusion criteria:<break/>&#x000a0;&#x0201c;surgical procedure in the past 7&#x000a0;days&#x0201d; was changed for &#x0201c;surgical procedure within 72&#x000a0;h, or any surgery associated with high risk of bleeding, or a planned surgery within 24&#x000a0;h&#x0201d;<break/>&#x000a0;&#x0201c;chronic liver disease&#x0201d; was clarified as &#x0201c;chronic liver disease with Child score C&#x0201d;<break/>&#x000a0;&#x0201c;severe thrombopenia&#x0201d; was clarified&#x0201d; as severe thrombopenia (&#x0003c;30,000/mm<sup>3</sup>, before transfusion)<break/>Minor wording modifications in title, study acronym, randomization paragraph<break/>Recruitment of 4 additional centers</td><td align="left">14/02/2008</td><td align="left">27/03/2008</td><td align="left">Protocol V2 dated 28/01/2008</td></tr><tr><td align="left">2</td><td align="left">Recruitment of 1 additional center<break/>Withdrawal of 1 center</td><td align="left">12/06/2008</td><td align="left">Not applicable</td><td align="left">Protocol V2 dated 28/01/2008 unchanged</td></tr><tr><td align="left">3</td><td align="left">Recruitment of 9 additional centers</td><td align="left">03/07/2008</td><td align="left">Not applicable</td><td align="left">Protocol V2 dated 28/01/2008 unchanged</td></tr><tr><td align="left">4</td><td align="left">Recruitment of 1 additional center</td><td align="left">13/11/2008</td><td align="left">Not applicable</td><td align="left">Protocol V2 dated 28/01/2008 unchanged</td></tr><tr><td align="left">5</td><td align="left">The time window for the use of a prepared (i.e., ready for infusion) infusion bag of Xigris and of its placebo was increased from 14&#x000a0;h to 24&#x000a0;h</td><td align="left">12/02/2009</td><td align="left">26/12/2008</td><td align="left">Protocol V3 dated 11/12/2008</td></tr><tr><td align="left">6</td><td align="left">Recruitment of 1 additional center<break/>Change in contact details of 3 centers</td><td align="left">15/01/2009</td><td align="left">Not applicable</td><td align="left">Protocol V3 dated 11/12/2008 unchanged</td></tr><tr><td align="left">7</td><td align="left">Recruitment of 1 additional center</td><td align="left">9/04/2009</td><td align="left">Not applicable</td><td align="left">Protocol V3 dated 11/12/2008 unchanged</td></tr><tr><td align="left">8</td><td align="left">Recruitment of 2 additional centers</td><td align="left">18/06/2009</td><td align="left">Not applicable</td><td align="left">Protocol V3 dated 11/12/2008 unchanged</td></tr><tr><td align="left">9</td><td align="left">The exclusion criteria: surgical procedure within 72&#x000a0;h, or any surgery associated with high risk of bleeding, or a planned surgery within 24 h &#x0201c;was changed for&#x0201d; surgical procedure within 12&#x000a0;h, or any surgery associated with high risk of bleeding</td><td align="left">17/09/2009</td><td align="left">25/08/2009</td><td align="left">Protocol V3.0 dated 20/07/2009</td></tr><tr><td align="left">10</td><td align="left">Recruitment of 1 additional center</td><td align="left">12/11/2009</td><td align="left">Not applicable</td><td align="left">Protocol V3.0 dated 20/07/2009 unchanged</td></tr><tr><td align="left">11</td><td align="left">Recruitment of 1 additional center</td><td align="left">10/12/2009</td><td align="left">Not applicable</td><td align="left">Protocol V3.0 dated 20/07/2009 unchanged</td></tr><tr><td align="left">12</td><td align="left">Recruitment of 1 additional center</td><td align="left">11/03/2010</td><td align="left">Not applicable</td><td align="left">Protocol V3.0 dated 20/07/2009 unchanged</td></tr><tr><td align="left">13</td><td align="left">Inclusion criteria: admitted to the ICU for &#x0003c;7&#x000a0;days was removed.<break/>New exclusion criteria: patients who had a previous episode of sepsis during the same hospital stay<break/>Prolongation of the recruitment period<break/>Recruitment of 3 additional centers<break/>Withdrawal of 11 inactive centers</td><td align="left">10/06/2010</td><td align="left">11/06/2010</td><td align="left">Protocol V4 dated 10/05/2010</td></tr><tr><td align="left">14</td><td align="left">Withdrawal of 4 inactive centers</td><td align="left">09/09/2010</td><td align="left">Not applicable</td><td align="left">Protocol V4 dated 10/05/2010 unchanged</td></tr><tr><td align="left">15</td><td align="left">Recruitment of 1 additional center</td><td align="left">23/11/2010</td><td align="left">Not applicable</td><td align="left">Protocol V4 dated 10/05/2010 unchanged</td></tr><tr><td align="left">16</td><td align="left">Recruitment of 1 additional center<break/>Implementation of biobanking: serum, plasma, DNA<break/>Change in informed consent sheet</td><td align="left">23/11/2010</td><td align="left">09/11/2010</td><td align="left">Protocol V6 dated 03/11/2010<break/>Informed consent sheet V1.1 dated 26/10/2010</td></tr><tr><td align="left">17</td><td align="left">Recruitment of 1 additional center</td><td align="left">13/10/2010</td><td align="left">Not applicable</td><td align="left">Protocol V6 dated 03/11/2010 unchanged</td></tr><tr><td align="left">18</td><td align="left">Recruitment of 7 additional centers</td><td align="left">13/01/2011</td><td align="left">Not applicable</td><td align="left">Protocol V6 dated 03/11/2010 unchanged</td></tr><tr><td align="left">19</td><td align="left">Recruitment of 1 additional center</td><td align="left">7/04/2011</td><td align="left">Not applicable</td><td align="left">Protocol V6 dated 03/11/2010 unchanged</td></tr><tr><td align="left">20</td><td align="left">Recruitment of 1 additional center</td><td align="left">12/05/2011</td><td align="left">Not applicable</td><td align="left">Protocol V6 dated 03/11/2010 unchanged</td></tr><tr><td align="left">20 BIS</td><td align="left">Following the withdrawal of DAA from the market:<break/>&#x000a0;Study design was modified from a 2&#x000a0;&#x000d7;&#x000a0;2 factorial to a two-parallel groups&#x02019; trial<break/>&#x000a0;Withdrawal of following exclusion criteria:<break/>&#x000a0;&#x000a0;(1) any surgery in the past 12&#x000a0;h, or any surgery associated with high risk of bleeding;<break/>&#x000a0;&#x000a0;(2) chronic liver disease with a Child score C;<break/>&#x000a0;&#x000a0;(3) recent trauma;<break/>&#x000a0;&#x000a0;(4) any intracranial mass, or stroke or head injury in the past 3&#x000a0;months;<break/>&#x000a0;&#x000a0;(5) severe thrombocytopenia (&#x0003c;30,000/mm<sup>3</sup>, before platelet transfusion);<break/>&#x000a0;&#x000a0;(6) formal indication for anticoagulation, or any other condition associated with increased risk of bleeding, as appreciated by the patient&#x02019;s physician<break/>Change in informed consent form</td><td align="left">10/02/2012</td><td align="left">18/04/2012</td><td align="left">Protocol V7 du 30/11/2011<break/>Informed consent sheet V3.0 dated 05/01/2012</td></tr><tr><td align="left">21</td><td align="left">Prolongation of recruitment period</td><td align="left">05/07/2012</td><td align="left">Not applicable</td><td align="left">Protocol V8 dated 27/06/2012<break/>Informed consent form V3.1 dated 21/09/2012</td></tr><tr><td align="left">22</td><td align="left">Recruitment of 2 additional centers</td><td align="left">13/09/2012</td><td align="left">Not applicable</td><td align="left">Protocol V9 dated 27/08/2012</td></tr><tr><td align="left">23</td><td align="left">Recruitment of 2 additional centers Withdrawal of 4 centers</td><td align="left">13/12/2012</td><td align="left">Not applicable</td><td align="left">Protocol V10 dated 04/12/2012</td></tr><tr><td align="left">24</td><td align="left">Recruitment of 2 additional centers<break/>Removal of exclusion criteria related to XIGRIS<break/>Withdrawal of 5 centers</td><td align="left">21/03/2013</td><td align="left">22/03/2013</td><td align="left">Protocol V11.0 dated 20/02/2013<break/>Protocol V11.1 dated 18/03/2013</td></tr><tr><td align="left">25</td><td align="left">Minor edits to the informed consent form upon CPP request</td><td align="left">24/04/2014</td><td align="left">Not applicable</td><td align="left">Protocol V12 du 15/10/2013<break/>Informed consent form V3.2 dated 21 01 2014</td></tr><tr><td align="left">26</td><td align="left">Suspension of inclusions upon DSMB request<break/>Changes in DSMB members</td><td align="left">18/09/2014</td><td align="left">29/08/2014</td><td align="left">Protocol V13 dated 24/07/2014</td></tr><tr><td align="left">27</td><td align="left">Request to restart inclusion following:<break/>(1) demonstration of the quality of study active drugs and placebos<break/>(2) advice from DSMB</td><td align="left">13/11/2014</td><td align="left">07/10/2014</td><td align="left">Protocol V13 dated 24/07/2014, unchanged</td></tr><tr><td align="left">28</td><td align="left">Prolongation of trial duration</td><td align="left">11/06/2015</td><td align="left">Not applicable</td><td align="left">Protocol V14.0 dated 12/05/2015</td></tr></tbody></table><table-wrap-foot><p>
<italic>CPP</italic> comit&#x000e9; de protection des personnes, <italic>ANSM</italic> Agence nationale de s&#x000e9;curit&#x000e9; des m&#x000e9;dicaments et produits de sant&#x000e9;</p></table-wrap-foot></table-wrap></p><p>The main substantial modification to the protocol was approved in October 2011, following DAA withdrawal from the market. Two study arms, i.e., active DAA and its placebo, were stopped, and the design was modified to a two parallel groups. As sample size was originally computed to show a 10&#x000a0;% absolute reduction in 90-day mortality between corticosteroids versus placebo-treated patients, or DAA versus placebo-treated patients, there was no need to modify it. DAA-related exclusion criteria were no longer justified and withdrawn (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). This last amendment to the protocol was associated with a significant (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) rise in recruitment rate into the study. There were 0.42&#x000a0;&#x000b1;&#x000a0;0.89 (range 0&#x02013;9, median 0 [0;1]) and 0.89&#x000a0;&#x000b1;&#x000a0;1.46 (range 0&#x02013;11, median 0 [0;1]) patients per site per month, before and after study amendment, respectively.</p></sec><sec id="Sec20"><title>Study monitoring</title><p>The Steering committee had monthly conference calls. The study site coordinator (Raymond Poincar&#x000e9; hospital) provided on-demand 24/7 services via phone calls or emails to advise investigators about patients&#x02019; eligibility or any other issues that may have risen between randomization and 180-day follow-up. There were a total of 28 face-to-face investigators meeting in which trial protocol and procedures were systematically recalled and investigators adherence and compliance to them discussed. A monthly electronic newsletter informed investigators on trial conduct and on any new information from sepsis literature.</p><p>DSMB met 5 times. DRRC organized data monitoring and quality audits. Baseline characteristics, eligibility criteria, primary outcome and serious adverse events reported in the CRF were systematically checked against original chart for all research participants. In addition, for one-third of study population, all data reported in CRF were validated against patient&#x02019;s original chart. Serious adverse events and major protocol violations were reported to DRRC, ANSM and CPP.</p><p>The study coordinator had quarterly face-to-face meeting with DRRC, AP-HP, independent pharmacists to monitor trial conduct according to highest standard for protection of research participants.</p><p>All randomized patients completed follow-up for the primary outcome and 180-day mortality data.</p></sec></sec><sec id="Sec21"><title>Discussion</title><p>This trial was designed to assess the role of DAA and corticosteroids in adult septic shock. Evaluation of DAA was terminated early owing to its withdrawal from the market by Lilly [<xref ref-type="bibr" rid="CR34">34</xref>]. We found no evidence for any benefit from DAA [<xref ref-type="bibr" rid="CR8">8</xref>]. Owing to the lack of interaction between DAA and corticosteroids, the trial continued to allow evaluation of corticosteroids. The study was suspended on request of DSMB to check safety issues. The two trial suspensions had no impact on its conduct, except delaying its completion. There were several amendments to the protocol mainly related to DAA. In particular, after DAA withdrawal from the market, corresponding exclusion criteria were removed and trial design changed for a two-parallel groups&#x02019; design. This amendment accelerated the recruitment rate into the trial. Then, we will explore any interaction between this change in the protocol and response to corticosteroids.</p><p>This trial replicated as much as possible Ger-Inf-05 [<xref ref-type="bibr" rid="CR10">10</xref>] contrasting with CORTICUS [<xref ref-type="bibr" rid="CR11">11</xref>] and ADRENAL [<xref ref-type="bibr" rid="CR35">35</xref>] trials (Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, <xref rid="Tab2" ref-type="table">2</xref>). APROCCHSS trial has investigated the effects of hydrocortisone and fludrocortisone at the same doses, durations and routes of administration than for Ger-Inf-05 [<xref ref-type="bibr" rid="CR10">10</xref>]. Likewise, it focused on patients with persistent vasopressor dependency and organ failure. Finally, non-responders [<xref ref-type="bibr" rid="CR16">16</xref>] were an a priori defined subgroup in analyzing corticosteroids effects.</p><sec id="Sec22"><title>Risk of bias assessment</title><p>First, selection biases were minimized. Allocating interventions to research participants used a random list which sequence was computer-generated by an independent statistician. To prevent forth knowledge of forth allocation, randomization was centralized through a secured Web site and used permutation blocks where size was not known by patients, nurses and physicians, investigators, pharmacists, and study sponsor. Thus, the allocation sequence was adequately concealed. Second, to minimize performance biases, we used a centralized procedure for masking corticosteroids and their placebos. Sites pharmacists received sealed boxes containing either active drugs or placebos in identical forms. Blood glucose levels were kept of &#x02264;150&#x000a0;mg/dl. Previous experiences from this group of investigators [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR36">36</xref>] as from others [<xref ref-type="bibr" rid="CR11">11</xref>] demonstrated that nurses, physicians and investigators can remain appropriately blinded to corticosteroids administration. Third, to prevent detection biases, for short-term and long-term outcomes, hospital staff, investigators, pharmacists and outcome assessors will remain blinded until public release of trial findings. Finally, there were no obvious attrition biases. There was no lost-to-follow-up for mortality data up to 180 days. According to French regulation, vital status of any citizen is publicly available at city hall of the town the citizen was born.</p><p>Other potential sources of bias may include the fact that the study design and statistical analysis plan were reported after all patients have been enrolled. This was done deliberately to also report the way the trial was conducted, in particular any amendment to the protocol. We did not plan any interim analysis and did not perform any. In fact, after the withdrawal of DAA from the market, we reported the analysis of the effects of this drug after checking for the absence of interaction with low-dose steroids. The code was never broken for corticosteroids, and all the parties involved in the trial remained fully blinded. Therefore, it is unlikely that the lack of reporting of the trial protocol before completion of recruitment may be a source of bias.</p><p>In conclusion, APROCCHSS trial is the only trial replicating Ger-Inf-05. Its design and conduct allowed appropriate minimization of risk of bias. It will provide sufficient reliable data to inform routine practice for management of adult septic shock. At the present time, the analysis is still pending, and all parties involved in this trial remain blinded.</p></sec></sec></body><back><app-group><app id="App1"><sec id="Sec23"><title>Appendix: Study organization</title><p><list list-type="bullet"><list-item><p><italic>Study chairs</italic>: Djillali Annane (Principal Investigator) and Eric Bellissant (Methodologist).</p></list-item><list-item><p><italic>Statistics and data management</italic>: Eric Bellissant and Alain Renault.</p></list-item><list-item><p><italic>Steering committee</italic>: Djillali Annane (chair), Eric Bellissant, Alain Cariou, Christian Brun Buisson, Claude Martin, Benoit Misset.</p></list-item><list-item><p><italic>Monitor</italic>: Val&#x000e9;rie Millul: D&#x000e9;l&#x000e9;gation &#x000e0; la Recherche Clinique, H&#x000f4;pital Saint-Louis, Paris.</p></list-item><list-item><p><italic>Monitoring</italic>: Layide Meaude: URC Paris Ouest, D&#x000e9;l&#x000e9;gation &#x000e0; la Recherche Clinique, H&#x000f4;pital Saint-Louis, Paris.</p></list-item><list-item><p><italic>Quality Assurance</italic>: D&#x000e9;l&#x000e9;gation &#x000e0; la Recherche Clinique, H&#x000f4;pital Saint-Louis, Paris.</p></list-item><list-item><p>Data safety and Monitoring Board: G&#x000e9;rard Nitenberg (chair) Jacques B&#x000e9;nichou, Didier Dreyfuss.</p></list-item><list-item><p><italic>Pharmacists</italic>: Blandine Lehmann: D&#x000e9;partement Essais Cliniques, AGEPS, AP-HP, Paris.</p></list-item></list><table-wrap id="Taba"><caption><p>Study centers and investigators</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Surname and name of sites principal investigator</th><th align="left">Study sites details</th></tr></thead><tbody><tr><td align="left">Annane, Djillali<break/>Fadel, Fouad<break/>Polito, Andrea<break/>Clair, Bernard<break/>Maxime, Virginie<break/>Luis, David</td><td align="left">Service de R&#x000e9;animation m&#x000e9;dicale<break/>HOPITAL RAYMOND POINCARE<break/>104 BD RAYMOND POINCARE<break/>92380 GARCHES</td></tr><tr><td align="left">Quenot, Jean-Pierre</td><td align="left">Service de r&#x000e9;animation<break/>14 RUE GAFFAREL BP 77908 21079 DIJON CEDEX<break/>H&#x000d4;PITAL F. MITTERRAND<break/>CHU DE DIJON</td></tr><tr><td align="left">Megarbane, Bruno</td><td align="left">Service de R&#x000e9;animation M&#x000e9;dicale et Toxicologique<break/>H&#x000f4;pital LARIBOISIERE<break/>2 rue AMBROISE PARE<break/>75010 PARIS</td></tr><tr><td align="left">Siami, Shidasp<break/>Percheron, St&#x000e9;phanie</td><td align="left">Service d&#x02019; Anesth&#x000e9;sie-r&#x000e9;animation du Dr. Lorenzo<break/>CENTRE HOSPITALIER D&#x02019;ETAMPES<break/>26 AV CHARLES DE GAULLE<break/>91150 ETAMPES</td></tr><tr><td align="left">Mignon, Alexandre<break/>Baudin, Francois<break/>Antona, Marion<break/>Meghenem, Alia<break/>Demesmay, Marine</td><td align="left">Service d&#x02019; Anesth&#x000e9;sie R&#x000e9;animation<break/>H&#x000f4;pital COCHIN<break/>27 R FAUBOURG ST-JACQUES<break/>75014 PARIS</td></tr><tr><td align="left">Forceville, Xavier<break/>Kuba-Kusuti, Jean-Kamiena<break/>Touati, Samia</td><td align="left">Service de R&#x000e9;animation Polyvalente<break/>CENTRE HOSPITALIER DE MEAUX<break/>6 R SAINT FIACRE<break/>77100 MEAUX</td></tr><tr><td align="left">Reignier, Jean<break/>Colin, Gwenha&#x000eb;l<break/>Martin-Lefevre, Laurent<break/>Bachoumas, Konstantinos<break/>Henry-Lagarrigue, Matthieu<break/>Yehia, Aihem<break/>Lascarrou, Jean-baptiste<break/>Lebert, Christine<break/>Lacherade, Jean-claude</td><td align="left">Service de r&#x000e9;animation<break/>CENTRE HOSPITALIER DEPARTEMENTAL<break/>SITE DE LA ROCHE-SUR-YONLES OUDAIRIES<break/>85925 LA ROCHE SUR YON CEDEX 9</td></tr><tr><td align="left">Asehnoune, Karim<break/>Loutrel, Olivier<break/>Dumont, Romain<break/>Roquilly, Antoine<break/>Mahe, Pierre-Joachim<break/>Demeure Dit Latte, Dominique<break/>Champin, Philippe<break/>Arnould, Jean Fran&#x000e7;ois<break/>Cinotti, Rapha&#x000eb;l<break/>Le Floch, Ronan</td><td align="left">Service d&#x02019;Anesth&#x000e9;sie R&#x000e9;animation chirurgicale,<break/>CHU DE NANTES<break/>19 RUE GENERAL MARGUERITTE, 44000 NANTES</td></tr><tr><td align="left">Mercier, Emmanuelle<break/>Garot, Denis<break/>Dequin, Pierre Fran&#x000e7;ois<break/>Perrotin, Dominique<break/>Legras, Annick<break/>Mankikian, Julie<break/>Talec, Patrice<break/>Ehrmann, Stephan<break/>Joret, Aur&#x000e9;lie<break/>Lhommet, Claire<break/>Joret, Aur&#x000e9;lie<break/>Lhommet, Claire<break/>Rouve, Emmanuelle<break/>Bodet-Contentin, Laetitia<break/>Jouan, Youenn<break/>Salmon-Gandonniere, Charlotte</td><td align="left">Service de r&#x000e9;animation polyvalente,<break/>CHU BRETONNEAU,<break/>2, BOULEVARD TONNELLE,<break/>37044 TOURS</td></tr><tr><td align="left">Antonini, Fran&#x000e7;ois<break/>Martin, Claude Denis<break/>Ragonnet, Beno&#x000ee;t</td><td align="left">Service d&#x02019; Anesth&#x000e9;sie R&#x000e9;animation<break/>HOPITAL NORD<break/>Chemin des BOURRELY<break/>13015 MARSEILLE</td></tr><tr><td align="left">Brun Buisson, Christian<break/>Razazi, Keyvan<break/>De Prost, Nicolas<break/>Carteaux, Guillaume</td><td align="left">Service de R&#x000e9;animation M&#x000e9;dicale<break/>H&#x000f4;pital HENRI MONDOR<break/>51 AV DE LATTRE DE TASSIGNY<break/>94010 CRETEIL</td></tr><tr><td align="left">Wolff, Michel<break/>Mourvillier, Bruno<break/>Timsit, Jean fran&#x000e7;ois</td><td align="left">Service de R&#x000e9;animation - Maladies Infectieuses<break/>H&#x000f4;pital BICHAT CLAUDE BERNARD<break/>46 Rue HENRI HUCHARD<break/>75018 PARIS</td></tr><tr><td align="left">Chagnon, Jean-Luc<break/>Ali Ben Ali, Mohamed</td><td align="left">Service de R&#x000e9;animation Polyvalente<break/>C.H. DE VALENCIENNES<break/>114 AV DESANDROUINS<break/>BP 479<break/>59322 VALENCIENNES</td></tr><tr><td align="left">Chimot, Loic<break/>Delour, Pierre<break/>Dessalles, Pierre Henri<break/>Monseau, Yannick<break/>Saint-Leger, M&#x000e9;lanie<break/>Bedon-Carte, Sandrine</td><td align="left">Service de R&#x000e9;animation<break/>CENTRE HOSPITALIER PERIGUEUX<break/>80, AVENUE GEORGES POMPIDOU<break/>CS 61205<break/>24019 PERIGUEUX CEDEX</td></tr><tr><td align="left">Boulain, Thierry<break/>Mathonnet, Armelle<break/>Bretagnol, Anne<break/>Runge, Isabelle<break/>Barbier, Fran&#x000e7;ois<break/>Muller, Gregoire</td><td align="left">Service de r&#x000e9;animation polyvalente<break/>CHR D&#x02019;ORLEANS<break/>1, RUE PORTE-MADELEINE &#x02013;<break/>45000ORLEANS</td></tr><tr><td align="left">Francois, Bruno<break/>Clavel, Marc<break/>Vignon, Philippe<break/>Pichon, Nicolas<break/>Fedou, Anne-Laure<break/>Chapellas, Catherine<break/>Galy, Antoine</td><td align="left">Service de r&#x000e9;animation polyvalente<break/>CHU LIMOGES<break/>2, AVENUE MARTIN LUTHER KING 87042 LIMOGES</td></tr><tr><td align="left">Timsit, Jean-Francois</td><td align="left">Service de R&#x000e9;animation m&#x000e9;dicale<break/>CHU DE GRENOBLE<break/>Avenue du Maquis du Gresivaudan, Pavillon Dauphin&#x000e9;<break/>BP 217<break/>38043 GRENOBLE</td></tr><tr><td align="left">Misset, Benoit<break/>Garrouste Orgeas, Mait&#x000e9;<break/>Philippart, Fran&#x000e7;ois</td><td align="left">Service de R&#x000e9;animation m&#x000e9;dicale polyvalente<break/>HOPITAL SAINT-JOSEPH<break/>185 R RAYMOND LOSSERAND<break/>75674 PARIS</td></tr><tr><td align="left">Souweine, Bertrand<break/>Ait-Hssain, Ali</td><td align="left">Service de R&#x000e9;animation<break/>CHU CLERMONT-FERRAND<break/>58 RUE MONTALEMBERT<break/>BP69<break/>63003 CLERMONT FERRAND</td></tr><tr><td align="left">Charpentier, Claire</td><td align="left">Service de R&#x000e9;animation chirurgicale<break/>HOPITAL CENTRAL<break/>29 AVENUE DU MARECHAL DE<break/>LATTRE DE TASSIGNY<break/>54037 NANCY</td></tr><tr><td align="left">Mignon, Alexandre<break/>Baudin, Francois<break/>Antona, Marion<break/>Meghenem, Alia<break/>Demesmay, Marine</td><td align="left">Service d&#x02019; Anesth&#x000e9;sie R&#x000e9;animation<break/>H&#x000f4;pital COCHIN<break/>27 R FAUBOURG ST-JACQUES<break/>75014 PARIS</td></tr><tr><td align="left">Petitpas, Franck<break/>Mimoz, Olivier<break/>Nanadoumgar, Hodanou</td><td align="left">Service de R&#x000e9;animation Chirurgicale<break/>H&#x000d4;PITAL DE LA MILETRIE<break/>2 RUE DE LA MILETRIE<break/>B. P. 577<break/>86021 POITIERS</td></tr><tr><td align="left">Chastre, Jean<break/>Combes, Alain<break/>Nieszkowska, Ania</td><td align="left">Service de R&#x000e9;animation M&#x000e9;dicale<break/>C.H.U. PITIE SALPETRIERE<break/>47 BOULEVARD DE L&#x02019;HOPITAL<break/>75013 PARIS</td></tr><tr><td align="left">Amathieu, Roland<break/>Levesque, Eric</td><td align="left">R&#x000e9;animations et surveillance continue chirurgicales HOPITAL HENRI MONDOR<break/>51 AV DE LATTRE DE TASSIGNY<break/>94010 CRETEIL</td></tr><tr><td align="left">Cook, Fabrice</td><td align="left">R&#x000e9;animations et surveillance continue chirurgicales<break/>HOPITAL HENRI MONDOR<break/>51 AV DE LATTRE DE TASSIGNY<break/>94010 CRETEIL</td></tr><tr><td align="left">Constantin, Jean-Michel<break/>Chartier, Christian<break/>Jabaudon, Mathieu<break/>Perbet, S&#x000e9;batien</td><td align="left">Service d&#x02019; Anesth&#x000e9;sie et r&#x000e9;animation<break/>H&#x000d4;PITAL HOTEL DIEU<break/>Boulevard L&#x000e9;on Malfreyt<break/>63058 CLERMONT FERRAND CEDEX 1</td></tr></tbody></table></table-wrap></p></sec></app></app-group><ack><title>Authors&#x02019; contributions</title><p>DA took the responsibility to coordinate the project, DA, CBB, AC, CM, BM and EB designed the protocol, AR and EB were responsible for the statistical plan, BL was responsible for the pharmaceutical aspects and study drug management, and VM was responsible for the regulatory and administrative management of the study. All authors read and approved the final manuscript. </p><sec id="FPar1"><title>Funding</title><p>The study was publicly funded by a grant from the Ministry of Health contract number P090902 and contract P 12-002-0030.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>M</given-names></name><name><surname>Deutschman</surname><given-names>CS</given-names></name><name><surname>Seymour</surname><given-names>CW</given-names></name><name><surname>Shankar-Hari</surname><given-names>M</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><etal/></person-group><article-title>The third international consensus definitions for sepsis and septic shock (Sepsis-3)</article-title><source>JAMA</source><year>2016</year><volume>315</volume><issue>8</issue><fpage>801</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.0287</pub-id><pub-id pub-id-type="pmid">26903338</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Bellissant</surname><given-names>E</given-names></name><name><surname>Cavaillon</surname><given-names>JM</given-names></name></person-group><article-title>Septic shock</article-title><source>Lancet</source><year>2005</year><volume>365</volume><fpage>63</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(04)17667-8</pub-id><pub-id pub-id-type="pmid">15639681</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Sharshar</surname><given-names>T</given-names></name></person-group><article-title>Cognitive decline after sepsis</article-title><source>Lancet Respir Med</source><year>2015</year><volume>3</volume><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(14)70246-2</pub-id><pub-id pub-id-type="pmid">25434614</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dellinger</surname><given-names>RP</given-names></name><name><surname>Levy</surname><given-names>MM</given-names></name><name><surname>Rhodes</surname><given-names>A</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Gerlach</surname><given-names>H</given-names></name><name><surname>Opal</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012</article-title><source>Intensive Care Med</source><year>2013</year><volume>39</volume><fpage>165</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1007/s00134-012-2769-8</pub-id><pub-id pub-id-type="pmid">23361625</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernard</surname><given-names>GR</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>Laterre</surname><given-names>PF</given-names></name><name><surname>LaRosa</surname><given-names>SP</given-names></name><name><surname>Dhainaut</surname><given-names>JF</given-names></name><name><surname>Lopez-Rodriguez</surname><given-names>A</given-names></name><name><surname>Steingrub</surname><given-names>JS</given-names></name><collab>Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group</collab><name><surname>Garber</surname><given-names>GE</given-names></name><name><surname>Helterbrand</surname><given-names>JD</given-names></name><name><surname>Ely</surname><given-names>EW</given-names></name><name><surname>Fisher</surname><given-names>CJ</given-names><suffix>Jr</suffix></name></person-group><article-title>Efficacy and safety of recombinant human activated protein C for severe sepsis</article-title><source>N Engl J Med</source><year>2001</year><volume>344</volume><fpage>699</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.1056/NEJM200103083441001</pub-id><pub-id pub-id-type="pmid">11236773</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>E</given-names></name><name><surname>Laterre</surname><given-names>PF</given-names></name><name><surname>Garg</surname><given-names>R</given-names></name><name><surname>Levy</surname><given-names>H</given-names></name><name><surname>Talwar</surname><given-names>D</given-names></name><name><surname>Trzaskoma</surname><given-names>BL</given-names></name><name><surname>Francois</surname><given-names>B</given-names></name><name><surname>Guy</surname><given-names>JS</given-names></name><name><surname>Bruckmann</surname><given-names>M</given-names></name><name><surname>Rea-Neto</surname><given-names>A</given-names></name><name><surname>Rossaint</surname><given-names>R</given-names></name><name><surname>Perrotin</surname><given-names>D</given-names></name><name><surname>Sablotzki</surname><given-names>A</given-names></name><name><surname>Arkins</surname><given-names>N</given-names></name><name><surname>Utterback</surname><given-names>BG</given-names></name><name><surname>Macias</surname><given-names>WL</given-names></name><collab>Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group</collab></person-group><article-title>Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death</article-title><source>N Engl J Med</source><year>2005</year><volume>353</volume><fpage>1332</fpage><lpage>1341</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa050935</pub-id><pub-id pub-id-type="pmid">16192478</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranieri</surname><given-names>VM</given-names></name><name><surname>Thompson</surname><given-names>BT</given-names></name><name><surname>Barie</surname><given-names>PS</given-names></name><name><surname>Dhainaut</surname><given-names>JF</given-names></name><name><surname>Douglas</surname><given-names>IS</given-names></name><name><surname>Finfer</surname><given-names>S</given-names></name><name><surname>Gardlund</surname><given-names>B</given-names></name><name><surname>Marshall</surname><given-names>JC</given-names></name><name><surname>Rhodes</surname><given-names>A</given-names></name><name><surname>Artigas</surname><given-names>A</given-names></name><name><surname>Payen</surname><given-names>D</given-names></name><name><surname>Tenhunen</surname><given-names>J</given-names></name><name><surname>Al-Khalidi</surname><given-names>HR</given-names></name><name><surname>Thompson</surname><given-names>V</given-names></name><name><surname>Janes</surname><given-names>J</given-names></name><name><surname>Macias</surname><given-names>WL</given-names></name><name><surname>Vangerow</surname><given-names>B</given-names></name></person-group><article-title>Williams MD; PROWESS-SHOCK Study Group. Drotrecogin alfa (Activated) in Adults with Septic Shock</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><fpage>2055</fpage><lpage>2064</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1202290</pub-id><pub-id pub-id-type="pmid">22616830</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Timsit</surname><given-names>JF</given-names></name><name><surname>Megarbane</surname><given-names>B</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Misset</surname><given-names>B</given-names></name><name><surname>Mourvillier</surname><given-names>B</given-names></name><name><surname>Siami</surname><given-names>S</given-names></name><name><surname>Chagnon</surname><given-names>JL</given-names></name><name><surname>Constantin</surname><given-names>JM</given-names></name><name><surname>Petitpas</surname><given-names>F</given-names></name><name><surname>Souweine</surname><given-names>B</given-names></name><name><surname>Amathieu</surname><given-names>R</given-names></name><name><surname>Forceville</surname><given-names>X</given-names></name><name><surname>Charpentier</surname><given-names>C</given-names></name><name><surname>Tesni&#x000e8;re</surname><given-names>A</given-names></name><name><surname>Chastre</surname><given-names>J</given-names></name><name><surname>Bohe</surname><given-names>J</given-names></name><name><surname>Colin</surname><given-names>G</given-names></name><name><surname>Cariou</surname><given-names>A</given-names></name><name><surname>Renault</surname><given-names>A</given-names></name><name><surname>Brun-Buisson</surname><given-names>C</given-names></name><name><surname>Bellissant</surname><given-names>E</given-names></name><collab>APROCCHSS Trial Investigators</collab></person-group><article-title>Recombinant human activated protein C for adults with septic shock: a randomized controlled trial</article-title><source>Am J Respir Crit Care Med</source><year>2013</year><volume>187</volume><issue>10</issue><fpage>1091</fpage><lpage>1097</lpage><pub-id pub-id-type="doi">10.1164/rccm.201211-2020OC</pub-id><pub-id pub-id-type="pmid">23525934</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Bellissant</surname><given-names>E</given-names></name><name><surname>Bollaert</surname><given-names>PE</given-names></name><name><surname>Briegel</surname><given-names>J</given-names></name><name><surname>Keh</surname><given-names>D</given-names></name><name><surname>Kupfer</surname><given-names>Y</given-names></name></person-group><article-title>Corticosteroids for treating sepsis</article-title><source>Cochrane Database Syst Rev</source><year>2015</year><volume>12</volume><fpage>CD002243</fpage><pub-id pub-id-type="pmid">26633262</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Sebille</surname><given-names>V</given-names></name><name><surname>Charpentier</surname><given-names>C</given-names></name><name><surname>Bollaert</surname><given-names>PE</given-names></name><name><surname>Fran&#x000e7;ois</surname><given-names>B</given-names></name><name><surname>Korach</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock</article-title><source>JAMA</source><year>2002</year><volume>288</volume><fpage>862</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1001/jama.288.7.862</pub-id><pub-id pub-id-type="pmid">12186604</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sprung</surname><given-names>C</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Keh</surname><given-names>D</given-names></name><name><surname>Moreno</surname><given-names>R</given-names></name><name><surname>Singer</surname><given-names>M</given-names></name><name><surname>Freivogel</surname><given-names>K</given-names></name><etal/></person-group><article-title>The CORTICUS randomized, double-blind, placebo-controlled study of hydrocortisone therapy in patients with septic shock</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>111</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa071366</pub-id><pub-id pub-id-type="pmid">18184957</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annane</surname><given-names>D</given-names></name></person-group><article-title>Adjunct therapy for sepsis: how early? current infectious disease reports</article-title><source>Curr Infect Dis Rep</source><year>2010</year><volume>12</volume><fpage>361</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1007/s11908-010-0123-2</pub-id><pub-id pub-id-type="pmid">21308518</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuksel</surname><given-names>M</given-names></name><name><surname>Okajima</surname><given-names>K</given-names></name><name><surname>Uchiba</surname><given-names>M</given-names></name><name><surname>Horiuchi</surname><given-names>S</given-names></name><name><surname>Okabe</surname><given-names>H</given-names></name></person-group><article-title>Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alfa production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes</article-title><source>Thromb Haemost</source><year>2002</year><volume>88</volume><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">12195699</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>MN</given-names></name><name><surname>Sternberg</surname><given-names>EM</given-names></name></person-group><article-title>Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction</article-title><source>Ann N Y Acad Sci</source><year>2012</year><volume>1261</volume><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2012.06633.x</pub-id><pub-id pub-id-type="pmid">22823394</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annane</surname><given-names>D</given-names></name></person-group><article-title>Corticosteroids for severe sepsis: an evidence-based guide for physicians</article-title><source>Ann Intensive Care</source><year>2011</year><volume>1</volume><issue>1</issue><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/2110-5820-1-7</pub-id><pub-id pub-id-type="pmid">21906332</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>S&#x000e9;bille</surname><given-names>V</given-names></name><name><surname>Troch&#x000e9;</surname><given-names>G</given-names></name><name><surname>Raphael</surname><given-names>JC</given-names></name><name><surname>Gajdos</surname><given-names>P</given-names></name><name><surname>Bellissant</surname><given-names>E</given-names></name></person-group><article-title>A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin</article-title><source>JAMA</source><year>2000</year><volume>283</volume><issue>8</issue><fpage>1038</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1001/jama.283.8.1038</pub-id><pub-id pub-id-type="pmid">10697064</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lagu</surname><given-names>T</given-names></name><name><surname>Rothberg</surname><given-names>MB</given-names></name><name><surname>Nathanson</surname><given-names>BH</given-names></name><name><surname>Pekow</surname><given-names>PS</given-names></name><name><surname>Steingrub</surname><given-names>JS</given-names></name><name><surname>Lindenauer</surname><given-names>PK</given-names></name></person-group><article-title>Variation in the care of septic shock: the impact of patient and hospital characteristics</article-title><source>J Crit Care</source><year>2012</year><volume>27</volume><fpage>329</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2011.12.003</pub-id><pub-id pub-id-type="pmid">22300489</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoneking</surname><given-names>L</given-names></name><name><surname>Denninghoff</surname><given-names>K</given-names></name><name><surname>Deluca</surname><given-names>L</given-names></name><name><surname>Keim</surname><given-names>SM</given-names></name><name><surname>Munger</surname><given-names>B</given-names></name></person-group><article-title>Sepsis bundles and compliance with clinical guidelines</article-title><source>J Intensive Care Med</source><year>2011</year><volume>26</volume><fpage>172</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1177/0885066610387988</pub-id><pub-id pub-id-type="pmid">21670090</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>de Mendonca</surname><given-names>A</given-names></name><name><surname>Cantraine</surname><given-names>F</given-names></name><etal/></person-group><article-title>Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study</article-title><source>Crit Care Med</source><year>1998</year><volume>26</volume><fpage>1793</fpage><lpage>1800</lpage><pub-id pub-id-type="doi">10.1097/00003246-199811000-00016</pub-id><pub-id pub-id-type="pmid">9824069</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other"><ext-link ext-link-type="uri" xlink:href="http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000000787078&#x00026;dateTexte">http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000000787078&#x00026;dateTexte</ext-link>. Accessed 2 Nov 2015.</mixed-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marti-Carvajal</surname><given-names>AJ</given-names></name><name><surname>Sola</surname><given-names>I</given-names></name><name><surname>Lathyris</surname><given-names>D</given-names></name><name><surname>Cardona</surname><given-names>AF</given-names></name></person-group><article-title>Human recombinant activated protein C for severe sepsis</article-title><source>Cochrane Database Syst Rev</source><year>2012</year><volume>3</volume><fpage>CD004388</fpage><pub-id pub-id-type="pmid">22419295</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dellinger</surname><given-names>RP</given-names></name><name><surname>Levy</surname><given-names>MM</given-names></name><name><surname>Carlet</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock</article-title><source>Crit Care Med</source><year>2008</year><volume>36</volume><fpage>296</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000298158.12101.41</pub-id><pub-id pub-id-type="pmid">18158437</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Guide &#x0201c;100 recommandations pour la surveillance et la pr&#x000e9;ventions des infections nosocomiales&#x0201d;. Bulletin &#x000e9;pid&#x000e9;miologique hebdomadaire du 30 novembre 1992. <ext-link ext-link-type="uri" xlink:href="http://www.invs.sante.fr/beh/1992/48/beh_48_1992.pdf">http://www.invs.sante.fr/beh/1992/48/beh_48_1992.pdf</ext-link>. Accessed 3 Nov 2015.</mixed-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knaus</surname><given-names>WA</given-names></name><name><surname>Zimmerman</surname><given-names>JE</given-names></name><name><surname>Wagner</surname><given-names>DP</given-names></name><name><surname>Draper</surname><given-names>EA</given-names></name><name><surname>Lawrence</surname><given-names>DE</given-names></name></person-group><article-title>APACHE-acute physiology and chronic health evaluation: a physiologically based classification system</article-title><source>Crit Care Med</source><year>1981</year><volume>9</volume><fpage>591</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1097/00003246-198108000-00008</pub-id><pub-id pub-id-type="pmid">7261642</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCabe</surname><given-names>WR</given-names></name><name><surname>Jackson</surname><given-names>GG</given-names></name></person-group><article-title>Gram-negative bacteremia: I. Etiology and ecology</article-title><source>Arch Intern Med</source><year>1962</year><volume>110</volume><fpage>847</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1001/archinte.1962.03620240029006</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Gall</surname><given-names>JR</given-names></name><name><surname>Lemeshow</surname><given-names>S</given-names></name><name><surname>Saulnier</surname><given-names>F</given-names></name></person-group><article-title>A new Simplified Acute Physiology Score (SAPSII) based on a European/North American multicenter study</article-title><source>JAMA</source><year>1993</year><volume>270</volume><fpage>2957</fpage><lpage>2963</lpage><pub-id pub-id-type="doi">10.1001/jama.1993.03510240069035</pub-id><pub-id pub-id-type="pmid">8254858</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno</surname><given-names>RP</given-names></name><name><surname>Metnitz</surname><given-names>PG</given-names></name><name><surname>Almeida</surname><given-names>E</given-names></name><name><surname>Jordan</surname><given-names>B</given-names></name><name><surname>Bauer</surname><given-names>P</given-names></name><name><surname>Campos</surname><given-names>RA</given-names></name><name><surname>Iapichino</surname><given-names>G</given-names></name><name><surname>Edbrooke</surname><given-names>D</given-names></name><name><surname>Capuzzo</surname><given-names>M</given-names></name><name><surname>Le</surname><given-names>Gall JR</given-names></name></person-group><article-title>From evaluation of the patient to evaluation of the intensive care unit. Part 2: Development of a prognostic model for hospital mortality at ICU admission</article-title><source>Intensive Care Med</source><year>2005</year><volume>31</volume><fpage>1345</fpage><lpage>1355</lpage><pub-id pub-id-type="doi">10.1007/s00134-005-2763-5</pub-id><pub-id pub-id-type="pmid">16132892</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathieu</surname><given-names>J</given-names></name><name><surname>DeBraekeleer</surname><given-names>M</given-names></name><name><surname>Pr&#x000e9;vost</surname><given-names>C</given-names></name><name><surname>Boily</surname><given-names>C</given-names></name></person-group><article-title>Myotonic dystrophy: clinical assessment of muscular disability in an isolated population with presumed homogeneous mutation</article-title><source>Neurology</source><year>1992</year><volume>42</volume><fpage>203</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1212/WNL.42.1.203</pub-id><pub-id pub-id-type="pmid">1734305</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ely</surname><given-names>EW</given-names></name><name><surname>Inouye</surname><given-names>SK</given-names></name><name><surname>Bernard</surname><given-names>GR</given-names></name><name><surname>Gordon</surname><given-names>S</given-names></name><name><surname>Francis</surname><given-names>J</given-names></name><name><surname>May</surname><given-names>L</given-names></name><name><surname>Truman</surname><given-names>B</given-names></name><name><surname>Speroff</surname><given-names>T</given-names></name><name><surname>Gautam</surname><given-names>S</given-names></name><name><surname>Margolin</surname><given-names>R</given-names></name><name><surname>Hart</surname><given-names>RP</given-names></name><name><surname>Dittus</surname><given-names>R</given-names></name></person-group><article-title>Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU)</article-title><source>JAMA</source><year>2001</year><volume>286</volume><fpage>2703</fpage><lpage>2710</lpage><pub-id pub-id-type="doi">10.1001/jama.286.21.2703</pub-id><pub-id pub-id-type="pmid">11730446</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leplege</surname><given-names>A</given-names></name><name><surname>Ecosse</surname><given-names>E</given-names></name><name><surname>Verdier</surname><given-names>A</given-names></name><name><surname>Perneger</surname><given-names>TV</given-names></name></person-group><article-title>The French SF-36 Health Survey: translation, cultural adaptation and preliminary psychometric evaluation</article-title><source>J Clin Epidemiol</source><year>1998</year><volume>51</volume><fpage>1013</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1016/S0895-4356(98)00093-6</pub-id><pub-id pub-id-type="pmid">9817119</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sundin</surname><given-names>EC</given-names></name><name><surname>Horowitz</surname><given-names>MJ</given-names></name></person-group><article-title>Impact of event scale: psychometric properties</article-title><source>Br J Psychiatry</source><year>2002</year><volume>180</volume><fpage>205</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1192/bjp.180.3.205</pub-id><pub-id pub-id-type="pmid">11872511</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zigmond</surname><given-names>AS</given-names></name><name><surname>Snaith</surname><given-names>RP</given-names></name></person-group><article-title>The hospital anxiety and depression scale</article-title><source>Acta Psychiatr Scand</source><year>1983</year><volume>67</volume><fpage>361</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0447.1983.tb09716.x</pub-id><pub-id pub-id-type="pmid">6880820</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annane</surname><given-names>D</given-names></name></person-group><article-title>Improving clinical trials in the critically ill: unique challenge&#x02014;sepsis</article-title><source>Crit Care Med</source><year>2009</year><volume>37</volume><fpage>S117</fpage><lpage>S128</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e318192078b</pub-id><pub-id pub-id-type="pmid">19104211</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Lilly Announces Withdrawal of Xigris (R) Following Recent Clinical Trial Results. <ext-link ext-link-type="uri" xlink:href="http://pi.lilly.com/us/xigris.pdf">http://pi.lilly.com/us/xigris.pdf</ext-link>. Accessed on 25 Oct 2011.</mixed-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatesh</surname><given-names>B</given-names></name><name><surname>Myburgh</surname><given-names>J</given-names></name><name><surname>Finfer</surname><given-names>S</given-names></name><name><surname>Webb</surname><given-names>SA</given-names></name><name><surname>Cohen</surname><given-names>J</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name><collab>ANZICS CTG Investigators</collab><etal/></person-group><article-title>The ADRENAL study protocol: adjunctive corticosteroid treatment in critically ill patients with septic shock</article-title><source>Critical Care Resusc</source><year>2013</year><volume>15</volume><fpage>83</fpage><lpage>88</lpage></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>COIITSS Study Investigators</collab></person-group><article-title>Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomised controlled trial</article-title><source>JAMA</source><year>2010</year><volume>303</volume><issue>4</issue><fpage>341</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1001/jama.2010.2</pub-id><pub-id pub-id-type="pmid">20103758</pub-id></element-citation></ref></ref-list></back></article>